SCHEMBL15824322

SCHEMBL15824322

NC(=O)c1nc(C2CC2)c(N2CCOCC2)c(-c2nnc[nH]2)c1-c1cscn1

nearest known ligand 0.30

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 1/20 0.30
PIK3CG P48736 1/20 0.30
JAK2 O60674 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15152985 0.84 EEF2K (0.31)
SCHEMBL15153084 0.68 IKBKB (0.36)
SCHEMBL15153078 0.68 SYK (0.36)
SCHEMBL15153065 0.66 ECE1 (0.35)
SCHEMBL15824319 0.66 MAP3K5 (0.43)
SCHEMBL252419 0.64
SCHEMBL998166 0.63 PDE10A (0.36)
SCHEMBL16826511 0.61 PIK3R2 (0.40) JAK2
SCHEMBL15824320 0.60 MAPK13 (0.32)
SCHEMBL15153029 0.60 IKBKB (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10307427-B2 Apoptosis signal-regulating kinase inhibitors GILEAD SCIENCES, INC. (US) 2019-06-04 US disclosed
US-20180303844-A1 APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS GILEAD SCIENCES, INC. 2018-10-25 US disclosed
US-9943521-B2 Apoptosis signal-regulating kinase inhibitors GILEAD SCIENCES, INC. (US) 2018-04-17 US disclosed
US-20170173031-A1 APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS GILEAD SCIENCES, INC. 2017-06-22 US disclosed
US-20150246910-A1 APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS GILEAD SCIENCES, INC. 2015-09-03 US disclosed
US-9051313-B2 Apoptosis signal-regulating kinase inhibitors GILDEAD SCIENCES, INC. (US) 2015-06-09 US disclosed
US-20140179663-A1 APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS GILEAD SCIENCES, INC. (US) 2014-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10307427-B2 Apoptosis signal-regulating kinase inhibitors AIFM1, DAPK1, MAP3K1 PIK3CA 1940/4885PIK3CG 1358/4885JAK2 855/4885
US-20140179663-A1 APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS AIFM1, MAP3K1, DAPK1 PIK3CA 1810/4885PIK3CG 1367/4885JAK2 857/4885
US-20150246910-A1 APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS AIFM1, MAP3K1, DAPK1 PIK3CA 1810/4885PIK3CG 1367/4885JAK2 857/4885
US-20180303844-A1 APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS AIFM1, DAPK1, MAP3K1 PIK3CA 1940/4885PIK3CG 1358/4885JAK2 855/4885
US-20170173031-A1 APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS AIFM1, MAP3K1, DAPK1 PIK3CA 1810/4885PIK3CG 1367/4885JAK2 857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.